Related Experiment Video
Updated: May 27, 2026
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Tenecteplase: a promising new fibrinolytic agent
M J De Jong1, W Sabadie-Garretson
1United States Air Force, Keesler Air Force Base, Mississippi, USA.
Dimensions of Critical Care Nursing : DCCN
|November 15, 2011
Summary
Tenecteplase is a new fibrinolytic drug for ST-elevation myocardial infarction (MI). It offers advantages over older agents for treating acute coronary syndrome, including acute MI.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Acute coronary syndrome (ACS) encompasses conditions from unstable angina to ST-elevation myocardial infarction (MI).
- Fibrinolytic therapy is a critical treatment for acute myocardial infarction.
- Newer agents aim to improve efficacy and safety in ACS management.
Purpose of the Study:
- To describe the actions, indications, contraindications, and clinical use of tenecteplase.
- To highlight the advantages of tenecteplase over existing fibrinolytic agents.
- To provide a comprehensive overview for clinicians managing ST-elevation MI.
Main Methods:
- Review of pharmacological properties of tenecteplase.
- Analysis of clinical trial data regarding tenecteplase efficacy and safety.
- Discussion of patient selection and administration protocols for tenecteplase.
Main Results:
- Tenecteplase demonstrates specific pharmacokinetic and pharmacodynamic advantages.
- Clinical data supports its role in reperfusion therapy for ST-elevation MI.
- Understanding contraindications is crucial for safe patient management.
Conclusions:
- Tenecteplase represents an advancement in fibrinolytic therapy for ST-elevation MI.
- Its distinct profile offers potential benefits in acute coronary syndrome treatment.
- Further research and clinical experience will continue to define its optimal use.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...